Drugs in Dev. Gastroenterology
Phase III
South Korea 
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Livzon Pharmaceutical Group
Deal Size : $127.5 million
Deal Type : Acquisition
Livzon Acquires Rights to GERD Therapy from Onconic for $127.5 Million
Details : Zastaprazan is a P-CAB (potassium-competitive acid-blocking) candidate, a class of drugs that is replacing existing PPIs (proton pump inhibitors) for peptic ulcer disease, including GERD. Livzon will have rights to JP 1366 (zastaprazan) in China, Taiwan,...
Product Name : JP 1366
Product Type : Other Small Molecule
Upfront Cash : $15.0 million
March 14, 2023
Lead Product(s) : Zastaprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Livzon Pharmaceutical Group
Deal Size : $127.5 million
Deal Type : Acquisition
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Shanghai Haini Pharmaceutical
Deal Size : $3,240.0 million
Deal Type : Licensing Agreement
Details : Under this agreement, Shanghai Haini (CEO Tan Pengfei) will clinically develop Fexuprazan and obtain marketing authorization, and then YRPG will be responsible for distributing the drug.
Product Name : Fexuclue
Product Type : Other Small Molecule
Upfront Cash : $6.0 million
March 18, 2021
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Shanghai Haini Pharmaceutical
Deal Size : $3,240.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In a Phase 3 clinical trial in patients with erosive esophagitis, conducted in 25 hospitals in Korea, Fexuprazan showed 99% of mucosal healing rate at week 8 and was well tolerated in the patients.
Product Name : DWP14012
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 05, 2020
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daewoong Pharmaceutical Announces Publication of Novel P-CAB Fexuprazan Phase 1 Bridging Study
Details : Bridging study results, published in the SCI journal, AP&T, demostrate no racial differences exist in pharmacokinetic and pharmacodynamic properties of fexuprazan.
Product Name : Fexuclue
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Fexuprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
